At the start of 2010, biotech companies that went public possessed more advanced technology and had reached later stages of their drug development cycle than the biotech companies raising public capital today. Following the Global Financial Crisis in 2008, biotech companies fell precipitously from their high participation in the IPO market of 2009 to fewer than 10% of IPOs subsequently.